Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date6/24/2020 (Estimated)
OptionableNot Optionable
Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions
What is Acasti Pharma's stock symbol?
Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."
How were Acasti Pharma's earnings last quarter?
Acasti Pharma Inc (NASDAQ:ACST) released its quarterly earnings results on Tuesday, January, 15th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. View Acasti Pharma's Earnings History.
When is Acasti Pharma's next earnings date?
What price target have analysts set for ACST?
6 brokerages have issued 12-month target prices for Acasti Pharma's shares. Their forecasts range from $2.00 to $7.00. On average, they expect Acasti Pharma's share price to reach $5.20 in the next twelve months. This suggests a possible upside of 812.3% from the stock's current price. View Analyst Price Targets for Acasti Pharma.
What is the consensus analysts' recommendation for Acasti Pharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acasti Pharma.
What are Wall Street analysts saying about Acasti Pharma stock?
Here are some recent quotes from research analysts about Acasti Pharma stock:
- 1. According to Zacks Investment Research, "Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada. " (1/14/2020)
- 2. HC Wainwright analysts commented, "Our price target of $6/share is based on an equally weighted composite of: (a) $4.96/share, as a 25x multiple of taxed and diluted 2030 EPS of $1.23 discounted back to FY 2020 at 20%; and (b) an NPV discounted cash flow between FY 2020-2030 of $6.32/share, with a discount rate of 13% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/15/2019)
Has Acasti Pharma been receiving favorable news coverage?
Media coverage about ACST stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acasti Pharma earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Acasti Pharma.
Are investors shorting Acasti Pharma?
Acasti Pharma saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,260,000 shares, an increase of 16.5% from the January 15th total of 1,940,000 shares. Based on an average trading volume of 4,370,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 3.3% of the company's shares are sold short. View Acasti Pharma's Current Options Chain.
What other stocks do shareholders of Acasti Pharma own?
Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the folowing people:
- Ms. Janelle D' Alvise, Pres, CEO & Director
- Dr. Pierre Lemieux, Co-Founder and Chief Operating & Scientific Officer
- Mr. Jean-François Boily, VP of Fin.
- Mr. Brian James Groch, Chief Commercial Officer (Age 52)
Who are Acasti Pharma's major shareholders?
Acasti Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.52%), Oxford Asset Management LLP (0.31%), Barclays PLC (0.11%), Bank of America Corp DE (0.09%), Oppenheimer & Co. Inc. (0.08%) and J. L. Bainbridge & Co. Inc. (0.07%). View Institutional Ownership Trends for Acasti Pharma.
Which major investors are selling Acasti Pharma stock?
Which major investors are buying Acasti Pharma stock?
ACST stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Renaissance Technologies LLC, Barclays PLC, Bank of America Corp DE, Sargent Investment Group LLC, Sargent Investment Group LLC, Huber Financial Advisors LLC and Schonfeld Strategic Advisors LLC. View Insider Buying and Selling for Acasti Pharma.
How do I buy shares of Acasti Pharma?
Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Acasti Pharma's stock price today?
One share of ACST stock can currently be purchased for approximately $0.57.
MarketBeat Community Rating for Acasti Pharma (NASDAQ ACST)
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.
